HilleVax 8/8/2024 Earnings Report $1.92 +0.03 (+1.32%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast HilleVax EPS ResultsActual EPS-$0.83Consensus EPS -$0.73Beat/MissMissed by -$0.10One Year Ago EPSN/AHilleVax Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHilleVax Announcement DetailsQuarterDate8/8/2024TimeAfter Market ClosesConference Call ResourcesPress ReleaseHLVX Earnings HistoryPowered by HilleVax Earnings HeadlinesHilleVax, Inc. Announces Workforce Reduction and Leadership ChangesDecember 5, 2024 | tipranks.comCautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves with Strategic UncertaintyNovember 12, 2024 | markets.businessinsider.comDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.January 22, 2025 | Weiss Ratings (Ad)HilleVax Reports Q3 Financial Results Amid Strategic PlanningNovember 9, 2024 | markets.businessinsider.comHilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback and Strategic ShiftNovember 9, 2024 | markets.businessinsider.comAVXL Aug 2024 12.500 put (AVXL240823P00012500)August 19, 2024 | finance.yahoo.comSee More HilleVax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email. Email Address About HilleVaxHilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.View HilleVax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Elevance Health (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)American Express (1/24/2025)HCA Healthcare (1/24/2025)NextEra Energy (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
